These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22080480)

  • 1. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
    Gupta M; Hendrickson AE; Yun SS; Han JJ; Schneider PA; Koh BD; Stenson MJ; Wellik LE; Shing JC; Peterson KL; Flatten KS; Hess AD; Smith BD; Karp JE; Barr S; Witzig TE; Kaufmann SH
    Blood; 2012 Jan; 119(2):476-87. PubMed ID: 22080480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
    Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
    Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
    Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
    Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
    Gupta M; Ansell SM; Novak AJ; Kumar S; Kaufmann SH; Witzig TE
    Blood; 2009 Oct; 114(14):2926-35. PubMed ID: 19641186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.
    Yun S; Vincelette ND; Knorr KL; Almada LL; Schneider PA; Peterson KL; Flatten KS; Dai H; Pratz KW; Hess AD; Smith BD; Karp JE; Hendrickson AE; Fernandez-Zapico ME; Kaufmann SH
    Blood; 2016 Jun; 127(22):2711-22. PubMed ID: 26917778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
    Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
    Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
    Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
    Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mTORC1/2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes.
    Chen J; Liu K; Liu Y; Wang X; Zhang Z
    Exp Dermatol; 2019 Mar; 28(3):270-275. PubMed ID: 30650200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.
    Shortt J; Martin BP; Newbold A; Hannan KM; Devlin JR; Baker AJ; Ralli R; Cullinane C; Schmitt CA; Reimann M; Hall MN; Wall M; Hannan RD; Pearson RB; McArthur GA; Johnstone RW
    Blood; 2013 Apr; 121(15):2964-74. PubMed ID: 23403624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.
    Chen B; Xu M; Zhang H; Xu MZ; Wang XJ; Tang QH; Tang JY
    DNA Cell Biol; 2015 Oct; 34(10):610-7. PubMed ID: 26284306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
    Márk Á
    Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
    Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
    J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTORC2 is required for proliferation and survival of TSC2-null cells.
    Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
    Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
    Meng H; Jin Y; Liu H; You L; Yang C; Yang X; Qian W
    J Hematol Oncol; 2013 Feb; 6():18. PubMed ID: 23415012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
    Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
    PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.